MedTrace Logo

Effect of Pectin and Inulin Fibre Supplementation on Glucose and ANS Modulation

NCT06480799 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-28

No results posted yet for this study

Summary

The study involves intake of dietary supplements, which are commonly found in the UK diet (not pharmacological agents) to test their effects on inflammation in the body and gut microbiome composition. Study subjects will be healthy volunteers recruited from the University and local population and will be asked to attend the laboratory on 2 occasions; before and after 4-week' supplementing the diet daily with either the dietary fibres (Pectin and Inulin) or placebo (maltodextrin). At each study visit (\~3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. They will also consume a glucose drink to assess how effectively the body regulates its blood glucose concentration. In the week before each study visit, participants will wear an activity and glucose monitor and record their food intake.

Conditions

  • Diet, Healthy
  • Systemic Inflammatory Response

Interventions

DIETARY_SUPPLEMENT

Fibre intervention

Inulin fibre (5g) and Pectin fibre (15g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.

DIETARY_SUPPLEMENT

Placebo intervention

Maltodextrin (10g) served as a control/ placebo to compare the effects observed with inulin and pectin.

Sponsors & Collaborators

  • Elizabeth Simpson

    lead OTHER

Principal Investigators

  • Ana Valdes, PhD · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2024-08-28
Completion
2024-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06480799 on ClinicalTrials.gov